New clues about brain growths in TSC and symptoms today

Credibility

Interest

Share:2 min read

Key Takeaway

Researchers found that the two main brain lesions in tuberous sclerosis (tubers and SEGAs) show very different molecular changes, with SEGAs showing strong signals that may drive their growth and inflammation.

What They Found

Tuber tissue (the brain spots linked to seizures and learning problems) showed signs of changes in how cells make energy (mitochondria), how nerve cells are shaped (cytoskeleton), and how neurons work, but did not show a clear signal for the main growth pathway called mTORC1.SEGAs (the benign brain tumors in TSC) showed strong activation of mTORC1, a cell growth and protein-making pathway; this is like a factory in overdrive making more parts and energy.In SEGAs, many proteins involved in making ribosomes (the cell's protein factories) were increased, and there was a strong inflammatory response, which is like a warning signal that brings immune activity to the area.The study found thousands of changes in phosphorylation (a chemical tag that turns proteins on or off) across many proteins in SEGAs, especially those that control how RNA is handled and sliced into final instructions.Consistent with the phosphorylation changes, SEGA tissue showed large changes in RNA splicing (the way cell messages are cut and pasted), a problem seen in some cancers and likely important for how SEGAs develop.

Who Should Care and Why

People with TSC and their caregivers should care because this helps explain why SEGAs grow and behave differently than nearby tubers, which may affect choices about monitoring and treatment.Knowing that SEGAs show strong mTORC1 activity supports why medicines that block mTOR (called mTOR inhibitors) can help shrink these tumors and reduce symptoms in many patients.This study suggests inflammation and changes in how cells process RNA are part of SEGA biology, so future treatments might target those processes too, similar to fixing a broken assembly line rather than just slowing the main motor.Neurologists and surgeons can use this information to better understand which lesion types are likely driven by active growth signals and might respond to drug therapy versus other approaches.For daily life, the findings mean that regular brain imaging and close follow-up remain important, and that patients can discuss with their care team whether mTOR-blocking drugs or other strategies are appropriate.

Important Considerations

The study used tissue samples from people with TSC, but tubers contain many different cell types and only some cells have the genetic change, so signals can be hard to detect in tubers.While SEGAs showed clear molecular changes, this does not immediately change treatment for every patient; clinical decisions should always be based on symptoms, imaging, and medical advice.These findings expand scientific understanding and point to new ideas for treatment, but more research and clinical trials are needed before new therapies based on RNA splicing or inflammation become standard care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Genetics Specific Symptoms

Article Topics:

PhosphoproteomicsSEGASignallingTSCTubermTOR

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Acta neuropathologica often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News